Literature DB >> 8135671

Serum level of magnesium attained in magnesium sulfate therapy for severe preeclampsia.

W Phuapradit1, N Saropala, S Haruvasin, P Thuvasethakul.   

Abstract

Serum magnesium levels were determined in severe preeclampsia patients who were treated with magnesium sulfate infusion. Forty-four patients with diagnosis of severe preeclampsia between 30-41 weeks gestation, given a conventional 5 g magnesium sulfate intravenous bolus infusion and 1 g/hr continuous infusion and continued 24 hours postpartum, were prospectively studied. The mean pre-treatment magnesium level was 2.3 +/- 0.3 mg/dl which was similar to those reports. The levels measured at 1/2, 1, 2, 4, 12 and 24 hours after initiation of magnesium infusion were 4.8 +/- 0.4, 4.7 +/- 0.4, 4.5 +/- 0.3, 4.7 +/- 0.3, 5.4 +/- 0.3 and 5.9 +/- 0.3 mg/dl respectively. After delivery the levels were measured immediately, 12, and 24 hours and found to be 4.7 +/- 0.4, 4.9 +/- 0.4, and 5.2 +/- 0.3 mg/dl respectively. The serum magnesium levels were also varied with maternal weight, the dose regimen used in our study is appropriate for Asian pregnant women whose body weight usually less than 70 kg.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8135671     DOI: 10.1111/j.1447-0756.1993.tb00398.x

Source DB:  PubMed          Journal:  Asia Oceania J Obstet Gynaecol        ISSN: 0389-2328


  4 in total

1.  Serum magnesium levels during magnesium sulfate infusion at 1 gram/hour versus 2 grams/hour as a maintenance dose to prevent eclampsia in women with severe preeclampsia: A randomized clinical trial.

Authors:  Ana C F Pascoal; Leila Katz; Marcela H Pinto; Carina A Santos; Luana C O Braga; Sabina B Maia; Melania M R Amorim
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

Review 2.  An integrative review of the side effects related to the use of magnesium sulfate for pre-eclampsia and eclampsia management.

Authors:  Jeffrey Michael Smith; Richard F Lowe; Judith Fullerton; Sheena M Currie; Laura Harris; Erica Felker-Kantor
Journal:  BMC Pregnancy Childbirth       Date:  2013-02-05       Impact factor: 3.007

Review 3.  Clinical pharmacokinetic properties of magnesium sulphate in women with pre-eclampsia and eclampsia.

Authors:  B O Okusanya; O T Oladapo; Q Long; P Lumbiganon; G Carroli; Z Qureshi; L Duley; J P Souza; A M Gülmezoglu
Journal:  BJOG       Date:  2015-11-24       Impact factor: 6.531

4.  Risk factors for sub-therapeutic serum concentrations of magnesium sulfate in severe preeclampsia of Chinese patients.

Authors:  Jingjing Li; Lian Tang; Ruiheng Tang; Lan Peng; Liqiang Chai; Liping Zhu; Yanxia Yu
Journal:  BMC Pregnancy Childbirth       Date:  2020-10-01       Impact factor: 3.007

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.